» Articles » PMID: 15990089

Role of 5'-nucleotidase in Thiopurine Metabolism: Enzyme Kinetic Profile and Association with Thio-GMP Levels in Patients with Acute Lymphoblastic Leukemia During 6-mercaptopurine Treatment

Overview
Journal Clin Chim Acta
Specialty Biochemistry
Date 2005 Jul 2
PMID 15990089
Citations 11
Authors
Affiliations
Soon will be listed here.
Abstract

Thiopurines are used for treatment of several diseases. Cytotoxicity is caused by the derived compounds 6-thioguanine nucleotides (TGNs) and methyl-6-thioinosine monophosphate (methylthio-IMP). The 6-thiopurine mononucleotides 6-thio-IMP (thio-IMP), 6-thio-GMP (thio-GMP) and methylthio-IMP can be catabolized by purine 5'-nucleotidase. It has been shown that the various 5'-nucleotidases are key enzymes for (6-thio)-purine metabolism. We aimed to investigate whether the overall 5'-nucleotidase (5'NT) activity is correlated with the efficacy and toxicity of 6-thiopurine nucleotides. Substrate affinity of 5'NT for IMP, GMP, AMP, thio-IMP, thio-GMP and methylthio-IMP was studied in human lymphocytes. For each of the substrates, the pH for optimal overall enzyme activity has been determined at a pH range between 6 and 10. At the optimal pH, assays were performed to establish Km and Vmax values. Optimal pH values for the various substrates were between 7 and 8.5. Km values ranged from 33 to 109 microM, Vmax ranged from 3.99 to 19.5 nmol/10(6) peripheral mononuclear cells (pMNC) h, and Vmax/Km ratios ranged from 105 to 250. The results did not show a distinct preference of 5'NT activity for any of the tested thiopurine nucleotides. The enzyme kinetic studies furthermore revealed substrate inhibition by thio-IMP and thio-GMP as a substrate. Inhibition by thio-GMP also seems to occur in patients treated with 6-mercaptopurine (6 MP); subsequently, this may lead to toxicity in these patients.

Citing Articles

Oncogenic deubiquitination controls tyrosine kinase signaling and therapy response in acute lymphoblastic leukemia.

Jin Q, Gutierrez Diaz B, Pieters T, Zhou Y, Narang S, Fijalkwoski I Sci Adv. 2022; 8(49):eabq8437.

PMID: 36490346 PMC: 9733937. DOI: 10.1126/sciadv.abq8437.


Optimizing thiopurine therapy in children with acute lymphoblastic leukemia: A promising "MINT" sequencing strategy and therapeutic "DNA-TG" monitoring.

Guo H, Zhao Y, Wang W, Dong N, Hu Y, Zhang Y Front Pharmacol. 2022; 13:941182.

PMID: 36238550 PMC: 9552076. DOI: 10.3389/fphar.2022.941182.


Pharmacologic Inhibition of NT5C2 Reverses Genetic and Nongenetic Drivers of 6-MP Resistance in Acute Lymphoblastic Leukemia.

Reglero C, Dieck C, Zask A, Forouhar F, Laurent A, Lin W Cancer Discov. 2022; 12(11):2646-2665.

PMID: 35984649 PMC: 9633388. DOI: 10.1158/2159-8290.CD-22-0010.


Strategies to Overcome Resistance Mechanisms in T-Cell Acute Lymphoblastic Leukemia.

Follini E, Marchesini M, Roti G Int J Mol Sci. 2019; 20(12).

PMID: 31226848 PMC: 6627878. DOI: 10.3390/ijms20123021.


Genetics and mechanisms of NT5C2-driven chemotherapy resistance in relapsed ALL.

Dieck C, Ferrando A Blood. 2019; 133(21):2263-2268.

PMID: 30910786 PMC: 6533602. DOI: 10.1182/blood-2019-01-852392.